Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.

− Transaction values Apollomics at pre-money equity value of $899 million − Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs − Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined $11 billion non-small cell lung cancer (“NSCLC”) and acute myeloid […]